No Data
Guangxi Wuzhou Zhongheng Group Co., Ltd. 2024 Annual Results Forecast Announcement
Product quantity and price have both declined, coupled with impairments in goodwill and intangible Assets. Guangxi Wuzhou Zhongheng Group expects a loss of 0.2 billion to -0.4 billion yuan in 2024 | Interpretations.
① Guangxi Wuzhou Zhongheng Group released its annual performance forecast for 2024, expecting a net loss of 0.22 billion yuan to -0.43 billion yuan, with the non-recurring net income also expecting a loss of 0.2 billion yuan to -0.4 billion yuan. ② Despite the performance pressure, Guangxi Wuzhou Zhongheng Group simultaneously announced multiple measures to maintain the company's stock price, including stock cancellations, share repurchases, and voluntary locks by major shareholders.
Guangxi Wuzhou Zhongheng Group (600252.SH) issued a pre-loss announcement, estimating a net loss of 0.43 billion yuan to 0.22 billion yuan for the year 2024.
Guangxi Wuzhou Zhongheng Group (600252.SH) released its annual performance forecast for 2024, projecting that the actual performance in 2024 will be...
Guangxi Wuzhou Zhongheng Group (600252.SH): Obtained a commitment letter for a Share Buyback loan from Financial Institutions.
On January 24, Gelonghui reported that Guangxi Wuzhou Zhongheng Group (600252.SH) announced that on January 23, 2025, the company obtained a Share Buyback loan commitment letter from the Bank Of Communications Wuzhou Branch (hereinafter referred to as "Bank Of Communications"), with a loan amount not exceeding 450 million yuan (RMB 450 million). The buyback is for part of the company's issued ordinary shares (A shares).
Guangxi Wuzhou Zhongheng Group (600252.SH): plans to spend 0.3 billion to 0.5 billion yuan to repurchase shares.
On January 24, Gelonghui announced that Guangxi Wuzhou Zhongheng Group (600252.SH) plans to repurchase shares for cancellation and to reduce the company's registered capital; the amount for the share repurchase will be no less than 300 million yuan (inclusive) and no more than 500 million yuan (inclusive); the repurchase price will not exceed 3.80 yuan per share.
Guangxi Wuzhou Zhongheng Group (600252.SH): The injection thrombus-dissolving agent (freeze-dried) is expected to win the bid for the national centralized procurement of Chinese Patent Medicine.
Guangxi Wuzhou Zhongheng Group (600252.SH) issued an announcement, based on the National Chinese Patent Medicine Joint Procurement Office in January 2024...
Lacklustre Performance Is Driving Guangxi Wuzhou Zhongheng Group Co.,Ltd's (SHSE:600252) Low P/S
